Allogene Therapeutics, a Phase 1 biotech developing off-the-shelf CAR T cell cancer therapies, raised $288 million by offering 16 million shares at $18, the high end of the range of $16 to $18. Allogene Therapeutics plans to list on the Nasdaq under the symbol ALLO. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as lead managers on the deal.
